Concentra Group Holdings Parent, Inc. (CON)vsEli Lilly and Company (LLY)
CON
Concentra Group Holdings Parent, Inc.
$22.47
+0.36%
HEALTHCARE · Cap: $2.90B
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 2913% more annual revenue ($65.18B vs $2.16B). LLY leads profitability with a 31.7% profit margin vs 7.7%. CON trades at a lower P/E of 17.4x. LLY earns a higher WallStSmart Score of 78/100 (B+).
CON
Buy59
out of 100
Grade: C
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+66.5%
Fair Value
$72.22
Current Price
$22.47
$49.75 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 48 in profit
Earnings expanding 60.1% YoY
Attractively priced relative to earnings
15.9% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
7.7% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CON
The strongest argument for CON centers on Return on Equity, EPS Growth, P/E Ratio. Revenue growth of 15.9% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : CON
The primary concerns for CON are Profit Margin, Piotroski F-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 59/100), backed by strong 31.7% margins and 42.6% revenue growth. CON offers better value entry with a 66.5% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Concentra Group Holdings Parent, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Concentra Group Holdings Parent, Inc. (Ticker: CON) is a diversified holding company that specializes in acquiring and managing businesses in high-growth sectors such as healthcare, technology, and infrastructure. With a commitment to operational excellence and innovation, Concentra leverages its seasoned leadership team to enhance portfolio performance through strategic investments and proactive management. This forward-looking approach positions the company to effectively capitalize on emerging trends and opportunities, making it an attractive investment for institutional investors aiming to diversify into high-potential industries.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?